Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Jun;25(6):733–740. doi: 10.1111/j.1365-2125.1988.tb05260.x

Alpha 1-acid glycoprotein concentration and molecular heterogeneity: relationship to oxprenolol binding in serum from healthy volunteers and patients with lung carcinoma or cirrhosis.

N F Fraeyman 1, C D Dello 1, F M Belpaire 1
PMCID: PMC1386451  PMID: 3203044

Abstract

1. alpha 1-acid glycoprotein (AAG) concentration and molecular heterogeneity, and oxprenolol protein binding were studied in serum of 15 healthy volunteers, 14 patients with lung carcinoma and 17 patients with liver cirrhosis. 2. The AAG serum concentration was increased to 180.7% in patients with lung cancer and decreased to 73.4% in cirrhotic patients as compared with controls (P less than 0.05). 3. The concanavalin A (conA) dependent heterogeneity of serum AAG was very similar in controls and patients with lung cancer: a ratio of 9/9/2 was obtained for the conA nonreactive, the conA weakly reactive and the conA strongly reactive subfraction respectively; in cirrhotic patients, the ratio shifted to 11/7/1. 4. The heterogeneity in electric charge, demonstrated by isoelectric focusing, was similar in the three groups of subjects: 70-80% of the focussed bands were found in the main three bands. 5. The binding of oxprenolol to serum proteins was increased in lung tumour patients and decreased in liver cirrhotic patients as compared with controls (P less than 0.05). There was no change in binding affinity and oxprenolol binding was significantly correlated to total AAG serum concentration and to the concentration of each of the conA dependent subtypes, in controls as well as in both patients groups.

Full text

PDF
733

Images in this article

736Figure 1
on p.736

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adan A., Farber E. R. Immunochemical and electrophoretic study of glycoproteins in cancer patients. Clin Biochem. 1982 Feb;15(1):22–23. doi: 10.1016/s0009-9120(82)90349-6. [DOI] [PubMed] [Google Scholar]
  2. Altland K., Roeder T., Jakin H. M., Zimmer H. G., Neuhoff V. Demonstration of alpha 1-acid glycoprotein (orosomucoid) by double one-dimensional slab gel electrophoresis: evidence for intra- and interindividual variability of the microheterogeneity pattern in health and disease. Clin Chem. 1982 Apr;28(4 Pt 2):1000–1010. [PubMed] [Google Scholar]
  3. Barre J., Houin G., Rosenbaum J., Zini R., Dhumeaux D., Tillement J. P. Decreased alpha 1-acid glycoprotein in liver cirrhosis: consequences for drug protein binding. Br J Clin Pharmacol. 1984 Oct;18(4):652–653. doi: 10.1111/j.1365-2125.1984.tb02525.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barre J., Mallat A., Rosenbaum J., Deforges L., Houin G., Dhumeaux D., Tillement J. P. Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity. Br J Clin Pharmacol. 1987 Jun;23(6):753–757. doi: 10.1111/j.1365-2125.1987.tb03111.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Belpaire F. M., Bogaert M. G., Rosseneu M. Binding of beta-adrenoceptor blocking drugs to human serum albumin, to alpha 1-acid glycoprotein and to human serum. Eur J Clin Pharmacol. 1982;22(3):253–256. doi: 10.1007/BF00545224. [DOI] [PubMed] [Google Scholar]
  6. Bleasby A. J., Knowles J. C., Cooke N. J. Microheterogeneity of alpha 1-acid glycoprotein: lack of discrimination between benign and malignant inflammatory disease of the lung. Clin Chim Acta. 1985 Aug 30;150(3):231–235. doi: 10.1016/0009-8981(85)90249-9. [DOI] [PubMed] [Google Scholar]
  7. Bordas M. C., Serbource-Goguel N. S., Feger J. M., Maccario J. M., Agneray J. M., Durand G. M. Evaluation of the degree of desialylation of serum alpha 1-acid glycoprotein and alpha 1-antitrypsin. Clin Chim Acta. 1982 Nov 10;125(3):311–318. doi: 10.1016/0009-8981(82)90262-5. [DOI] [PubMed] [Google Scholar]
  8. Bøg-Hansen T. C., Prahl P., Løwenstein H. A set of analytical electrophoresis experiments to predict the results of affinity chromatographic separations: fractionation of allergens from cow's hair and dander. J Immunol Methods. 1978;22(3-4):293–307. doi: 10.1016/0022-1759(78)90037-6. [DOI] [PubMed] [Google Scholar]
  9. Chio L. F., Oon C. J. Changes in serum alpha 1 antitrypsin, alpha1 acid glycoprotein and beta 2 glycoprotein I in patients with malignant hepatocellular carcinoma. Cancer. 1979 Feb;43(2):596–604. doi: 10.1002/1097-0142(197902)43:2<596::aid-cncr2820430229>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  10. Doumas B. T., Watson W. A., Biggs H. G. Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta. 1971 Jan;31(1):87–96. doi: 10.1016/0009-8981(71)90365-2. [DOI] [PubMed] [Google Scholar]
  11. Edwards D. J., Lalka D., Cerra F., Slaughter R. L. Alpha1-acid glycoprotein concentration and protein binding in trauma. Clin Pharmacol Ther. 1982 Jan;31(1):62–67. doi: 10.1038/clpt.1982.10. [DOI] [PubMed] [Google Scholar]
  12. Jackson P. R., Tucker G. T., Woods H. F. Altered plasma drug binding in cancer: role of alpha 1-acid glycoprotein and albumin. Clin Pharmacol Ther. 1982 Sep;32(3):295–302. doi: 10.1038/clpt.1982.163. [DOI] [PubMed] [Google Scholar]
  13. Krotoski W. A., Weimer H. E. Effects of dilute acids on the chemical and immunochemical properties of human orosomucoid. Clin Chim Acta. 1966 Mar;13(3):329–340. doi: 10.1016/0009-8981(66)90212-9. [DOI] [PubMed] [Google Scholar]
  14. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci. 1982;389:39–48. doi: 10.1111/j.1749-6632.1982.tb22124.x. [DOI] [PubMed] [Google Scholar]
  15. Laurell C. B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem. 1966 Apr;15(1):45–52. doi: 10.1016/0003-2697(66)90246-6. [DOI] [PubMed] [Google Scholar]
  16. Nicollet I., Lebreton J. P., Fontaine M., Hiron M. Evidence for alpha-1-acid glycoprotein populations of different pI values after concanavalin A affinity chromatography. Study of their evolution during inflammation in man. Biochim Biophys Acta. 1981 Apr 28;668(2):235–245. doi: 10.1016/0005-2795(81)90031-3. [DOI] [PubMed] [Google Scholar]
  17. Paxton J. W. Alpha 1 -acid glycoprotein and binding of basic drugs. Methods Find Exp Clin Pharmacol. 1983 Nov;5(9):635–648. [PubMed] [Google Scholar]
  18. Pedersen L. E., Bonde J., Graudal N. A., Backer N. V., Hansen J. E., Kampmann J. P. Quantitative and qualitative binding characteristics of disopyramide in serum from patients with decreased renal and hepatic function. Br J Clin Pharmacol. 1987 Jan;23(1):41–46. doi: 10.1111/j.1365-2125.1987.tb03007.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Piafsky K. M., Borgá O., Odar-Cederlöf I., Johansson C., Sjöqvist F. Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. N Engl J Med. 1978 Dec 28;299(26):1435–1439. doi: 10.1056/NEJM197812282992604. [DOI] [PubMed] [Google Scholar]
  20. Rosenthal H. E. A graphic method for the determination and presentation of binding parameters in a complex system. Anal Biochem. 1967 Sep;20(3):525–532. doi: 10.1016/0003-2697(67)90297-7. [DOI] [PubMed] [Google Scholar]
  21. Routledge P. A. The plasma protein binding of basic drugs. Br J Clin Pharmacol. 1986 Nov;22(5):499–506. doi: 10.1111/j.1365-2125.1986.tb02927.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Shibata K., Okubo H., Ishibashi H., Kawamura K. Human alpha1-acid glycoprotein: purification from urine proteins and immunological estimation of its serum concentration. Biochem Med. 1975 Jul;13(3):251–260. doi: 10.1016/0006-2944(75)90082-4. [DOI] [PubMed] [Google Scholar]
  23. Teirlynck O., Belpaire F. M., Andreasen F. Binding of aprindine and moxaprindine to human serum, alpha 1-acid glycoprotein and serum of healthy and diseased humans. Eur J Clin Pharmacol. 1982;21(5):427–431. doi: 10.1007/BF00542331. [DOI] [PubMed] [Google Scholar]
  24. Tinguely D., Baumann P., Conti M., Jonzier-Perey M., Schöpf J. Interindividual differences in the binding of antidepressives to plasma proteins: the role of the variants of alpha 1-acid glycoprotein. Eur J Clin Pharmacol. 1985;27(6):661–666. doi: 10.1007/BF00547045. [DOI] [PubMed] [Google Scholar]
  25. Wallace S. M., Verbeeck R. K. Plasma protein binding of drugs in the elderly. Clin Pharmacokinet. 1987 Jan;12(1):41–72. doi: 10.2165/00003088-198712010-00004. [DOI] [PubMed] [Google Scholar]
  26. Wells C., Bøg-Hansen T. C., Cooper E. H., Glass M. R. The use of concanavalin A crossed immuno-affinoelectrophoresis to detect hormone-associated variations in alpha 1-acid glycoprotein. Clin Chim Acta. 1981 Jan 8;109(1):59–67. doi: 10.1016/0009-8981(81)90137-6. [DOI] [PubMed] [Google Scholar]
  27. Wood M., Wood A. J. Changes in plasma drug binding and alpha 1-acid glycoprotein in mother and newborn infant. Clin Pharmacol Ther. 1981 Apr;29(4):522–526. doi: 10.1038/clpt.1981.73. [DOI] [PubMed] [Google Scholar]
  28. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn. 1981 Nov;4(11):879–885. doi: 10.1248/bpb1978.4.879. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES